CTLA4 and cancer: A better understanding of the biological mechanisms and functions of negative and positive co-stimulatory molecules has been shown to be essential for improving current and potentially new CTLA-4 or Programmed Cell Death 1 (PD-1) inhibitors for anti-cancer immunotherapies.